{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:25:13Z","timestamp":1767907513189,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.euf.2023.04.002","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T15:41:55Z","timestamp":1682523715000},"page":"966-973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Physician Perception of Grade Group 1 Prostate Cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"Ragheed","family":"Saoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varat","family":"Woranisarakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladell P.","family":"Paner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Ramotar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott E.","family":"Eggener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2023.04.002_b0005","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae): prostate cancer version 2.2022. Plymouth Meeting, PA: NCCN; 2021."},{"key":"10.1016\/j.euf.2023.04.002_b0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/JU.0000000000002341","article-title":"Active surveillance: very much \u201cpreferred\u201d for low-risk prostate cancer","volume":"207","author":"Cooperberg","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.04.002_b0015","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part I: risk stratification, shared decision making, and care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.04.002_b0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.04.002_b0025","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2023.04.002_b0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.juro.2015.08.087","article-title":"Outcomes of active surveillance for clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort","volume":"195","author":"Newcomb","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.04.002_b0035","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.04.002_b0040","doi-asserted-by":"crossref","first-page":"E509","DOI":"10.1016\/S1470-2045(12)70388-1","article-title":"Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2023.04.002_b0045","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1159\/000441735","article-title":"Gleason score 6\u2014prostate cancer or benign variant?","volume":"38","author":"Kn\u00fcchel","year":"2015","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.euf.2023.04.002_b0050","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.juro.2010.10.057","article-title":"Predicting 15-year prostate cancer specific mortality after radical prostatectomy","volume":"185","author":"Eggener","year":"2011","journal-title":"J Urol"},{"issue":"5 Suppl","key":"10.1016\/j.euf.2023.04.002_b0055","first-page":"e740","article-title":"MP43-03 Active surveillance for low-risk prostate cancer: time, trends and variation in the AUA Quality (AQUA) registry","volume":"207","author":"Cooperberg","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.04.002_b0060","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1464-410X.2010.09514.x","article-title":"Trends in the treatment of localized prostate cancer using supplemented cancer registry data","volume":"107","author":"Hamilton","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2023.04.002_b0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.urology.2016.12.063","article-title":"The influence of psychosocial constructs on the adherence to active surveillance for localized prostate cancer in a prospective, population-based cohort","volume":"103","author":"Lang","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.euf.2023.04.002_b0070","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","article-title":"Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American Society of Clinical Oncology clinical practice guideline endorsement","volume":"34","author":"Chen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2023.04.002_b0075","unstructured":"Prostate Cancer Foundation of Australia and Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. Clinical practice guidelines: PSA testing and early management of test-detected prostate cancer. Sydney: Cancer Council Australia; 2016."},{"key":"10.1016\/j.euf.2023.04.002_b0080","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/cncr.23807","article-title":"Predictors of patient preferences and treatment choices for localized prostate cancer","volume":"113","author":"Sommers","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2023.04.002_b0085","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jamainternmed.2016.4426","article-title":"Physician-driven variation in nonrecommended services among older adults diagnosed with cancer","volume":"176","author":"Lipitz-Snyderman","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.euf.2023.04.002_b0090","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1186\/s12885-021-08386-3","article-title":"Perceived barriers to the adoption of active surveillance in low-risk prostate cancer: a qualitative analysis of community and academic urologists","volume":"21","author":"Ellis","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2023.04.002_b0095","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jamaoncol.2016.3600","article-title":"Uptake of active surveillance for very-low-risk prostate cancer in Sweden","volume":"3","author":"Loeb","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2023.04.002_b0100","doi-asserted-by":"crossref","first-page":"e2031349","DOI":"10.1001\/jamanetworkopen.2020.31349","article-title":"Regional variation in active surveillance for low-risk prostate cancer in the US","volume":"3","author":"Washington","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euf.2023.04.002_b0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/jamasurg.2016.2907","article-title":"Urologist-level correlation in the use of observation for low- and high-risk prostate cancer","volume":"152","author":"Tyson","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.euf.2023.04.002_b0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cncr.30983","article-title":"Variation in the use of active surveillance for low-risk prostate cancer","volume":"124","author":"L\u00f6ppenberg","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2023.04.002_b0115","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MOU.0b013e328352598c","article-title":"Active surveillance: the Canadian experience","volume":"22","author":"Klotz","year":"2012","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2023.04.002_b0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/SLA.0b013e3181cbcc9a","article-title":"National and surgical health care expenditures, 2005\u20132025","volume":"251","author":"Mu\u00f1oz","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.euf.2023.04.002_b0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2016.11.028","article-title":"Extraprostatic extension is extremely rare for contemporary Gleason score 6 prostate cancer","volume":"72","author":"Anderson","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.04.002_b0130","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.juro.2015.01.126","article-title":"Gleason 6 prostate cancer: translating biology into population health","volume":"194","author":"Eggener","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.04.002_b0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.04.002_b0140","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1200\/JCO.2012.42.8466","article-title":"Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer","volume":"30","author":"Aizer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2023.04.002_b0145","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2012.44.0586","article-title":"Gleason score 6 adenocarcinoma: should it be labeled as cancer?","volume":"30","author":"Carter","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2023.04.002_b0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00345-020-03583-4","article-title":"Should grade group 1 (GG 1) be called cancer?","volume":"40","author":"Labbate","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2023.04.002_b0155","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/PAS.0b013e3182556dcd","article-title":"Do adenocarcinomas of the prostate with Gleason score (GS) \u22646 have the potential to metastasize to lymph nodes?","volume":"36","author":"Ross","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euf.2023.04.002_b0160","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/1055-9965.EPI-16-0237","article-title":"Perineural invasion and risk of lethal prostate cancer","volume":"26","author":"Zareba","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.euf.2023.04.002_b0165","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.eururo.2018.05.014","article-title":"The diverse genomic landscape of clinically low-risk prostate cancer","volume":"74","author":"Cooperberg","year":"2018","journal-title":"Eur Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923000998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923000998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:54:56Z","timestamp":1762498496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456923000998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2405456923000998"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2023.04.002","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physician Perception of Grade Group 1 Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2023.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}